tiprankstipranks
OncoZenge AB (DE:8LY)
FRANKFURT:8LY
Germany Market

OncoZenge AB (8LY) Income Statement

0 Followers

OncoZenge AB Income Statement

Last quarter (Q2 2022), OncoZenge AB's total revenue was kr0.00, a decrease of ― from the same quarter last year. In Q2, OncoZenge AB's net income was kr-2.82M. See OncoZenge AB’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Dec 21Dec 20
Total Revenue
-kr 0.00kr 0.00
Cost of Revenue
-kr 0.00-
Gross Profit
-kr 0.00-
Operating Expense
kr 37.90Mkr 4.89Mkr 801.00K
Operating Income
kr -37.90Mkr -4.89Mkr -801.00K
Net Non Operating Interest Income Expense
-kr 0.00kr 0.00
Other Income Expense
---
Pretax Income
kr -37.90Mkr -4.89Mkr -801.00K
Tax Provision
kr 2.77Mkr -1.01Mkr -165.00K
Earnings From Equity Interest Net Of Tax
---
Net Income Common Stockholders
kr -40.67Mkr -3.89Mkr -636.00K
Basic EPS
kr -3.48kr -0.33kr -0.09
Diluted EPS
kr -3.48kr -0.33kr -0.09
Basic Average Shares
kr 46.38Mkr 11.71Mkr 7.27M
Diluted Average Shares
kr 46.38Mkr 11.71Mkr 7.27M
Dividend Per Share
---
Total Operating Income As Reported
---
Reported Normalized Basic E P S
---
Reported Normalized Diluted E P S
---
Rent Expense Supplemental
---
Total Expenses
kr 37.90Mkr 4.89Mkr 801.00K
Net Income From Continuing And Discontinued Operation
kr -40.67Mkr -3.89Mkr -636.00K
Normalized Income
kr -40.67Mkr -3.89Mkr -636.00K
Interest Expense
-kr 0.00kr 0.00
EBIT
kr -37.90Mkr -4.89Mkr -801.00K
EBITDA
kr -14.73Mkr -4.89Mkr -801.00K
Currency in SEK

OncoZenge AB Earnings and Revenue History

What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis